38
Participants
Start Date
August 5, 2017
Primary Completion Date
March 30, 2020
Study Completion Date
June 15, 2020
BIO-11006
"Intervention involves aerosolized delivery of either the active drug or placebo by the Aeroneb Pro nebulizer."
Placebo
"Intervention involves aerosolized delivery of either the active drug or placebo by the Aeroneb Pro nebulizer."
University of Pennsylvania, Philadelphia
Wake Forest University, Winston-Salem
University of North Carolina School of Medicine, Chapel Hill
Vanderbilt University, Div of Allergy, Pulmonary, Critical Care, Nashville
University of Chicago Medicine, Chicago
Lead Sponsor
BioMarck Pharmaceuticals, Ltd.
INDUSTRY